To explore the potential of topical cannabinoids in managing ocular pain through modulation of the endocannabinoid system (ECS).
Approach:
ECS Overview: The ECS consists of receptors, endogenous cannabinoids, and enzymes, and is present in ocular tissues, influencing pain transmission.
Cannabinoid Receptors: CB1R is found throughout ocular tissues, while CB2R is primarily on immune cells, both playing roles in pain and inflammation.
Topical Cannabinoids: Topical cannabinoids can target the corneal epithelium and lacrimal gland, potentially alleviating acute and chronic ocular pain.
ECS Modulation Methods: Investigations into ECS modulation include enhancing cannabinoid receptor binding and using enzyme inhibitors to increase endocannabinoid levels.
Challenges: Hydrophobic nature of ECS modulators poses challenges for ocular penetration and bioavailability, with nanotechnology-based delivery methods being explored.
Key Findings:
Topical cannabinoids may provide significant pain relief for dry eye disease (DED) patients.
CB1R activation can reduce sensitization of lacrimal gland nerves, potentially alleviating chronic pain.
Treatment with enzyme inhibitors has been shown to reduce pain and inflammation in several preclinical models.
Interpretation:
Limitations:
ECS modulators face challenges with ocular penetration and bioavailability.
